Rate My Professor Anna Wredenberg

The Wredenberg group focuses on mitochondrial metabolism in health and disease, examining how mitochondrial dysfunction affects cellular processes, particularly energy metabolism, and regulatory mechanisms of mitochondrial DNA and RNA metabolism. Research explores influences on mitochondrial gene expression, RNA turnover, mitochondrial dynamics, and defects in inborn errors of metabolism, with implications for common diseases including heart disease, diabetes, cancers, neurodegeneration, and autoimmune disorders. The group utilizes Drosophila melanogaster models, mammalian systems, primary patient cells, reprogrammed neuronal stem cells, and multi-omics approaches, in close collaboration with clinical settings for novel disease validation. Key publications include 'The mitochondrial methylation potential gates mitoribosome assembly' (Nature Communications, 2025, Glasgow et al.), 'Preventing excessive autophagy protects from the pathology of mtDNA mutations in Drosophila melanogaster' (Nature Communications, 2024, El Fissi et al.), 'Quantitative proteomics of patient fibroblasts reveal biomarkers and diagnostic signatures of mitochondrial disease' (JCI Insight, 2024, Correia et al.), 'MTERF3 regulates mitochondrial ribosome biogenesis in invertebrates and mammals' (PLoS Genetics, 2013, Wredenberg et al.), and 'Premature ageing in mice expressing defective mitochondrial DNA polymerase' (Nature, 2004, Trifunovic et al.). Wredenberg has been awarded the Ragnar Söderberg Fellowship in Medicine (2013, 8 million SEK), a Novo Nordisk Foundation grant (2018, DKK 5 million), and Wallenberg Foundation funding (2024, SEK 24 million).